BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10601089)

  • 1. Correlation of endocrine profiles with bleeding patterns during use of Nestorone contraceptive implants.
    Faúndes A; Alvarez F; Brache V; Cochón L; Tejada AS; Moo-Young A
    Hum Reprod; 1999 Dec; 14(12):3013-7. PubMed ID: 10601089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.
    Fraser IS; Weisberg E; Minehan E; Johansson ED
    Contraception; 2000 Apr; 61(4):241-51. PubMed ID: 10899479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants.
    Faúndes A; Alvarez-Sanchez F; Brache V; Jimenez E; Tejada AS
    Adv Contracept; 1991 Mar; 7(1):85-94. PubMed ID: 1908178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
    Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
    Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
    Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
    Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian function during use of Nestorone(R) subdermal implants.
    Brache V; Massai R; Mishell DR; Moo-Young AJ; Alvarez F; Salvatierra AM; Cochon L; Croxatto H; Robbins A; Faundes A
    Contraception; 2000 Mar; 61(3):199-204. PubMed ID: 10827334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
    Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
    Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial with Nestorone subdermal contraceptive implants.
    Díaz S; Schiappacasse V; Pavez M; Zepeda A; Moo-Young AJ; Brandeis A; Lähteenmäki P; Croxatto HB
    Contraception; 1995 Jan; 51(1):33-8. PubMed ID: 7750282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
    Laurikka-Routti M; Haukkamaa M
    Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
    Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Sivin I; Tsong YY; Fraser IS
    Contraception; 2005 Jul; 72(1):46-52. PubMed ID: 15964292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
    Brache V; Mishell DR; Lahteenmaki P; Alvarez F; Elomaa K; Jackanicz T; Faundes A
    Contraception; 2001 May; 63(5):257-61. PubMed ID: 11448466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women.
    Massai MR; Díaz S; Quinteros E; Reyes MV; Herreros C; Zepeda A; Croxatto HB; Moo-Young AJ
    Contraception; 2001 Dec; 64(6):369-76. PubMed ID: 11834236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial angiogenic response in Norplant users.
    Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
    Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users.
    Lau TM; Witjaksono J; Affandi B; Rogers PA
    Hum Reprod; 1996 Dec; 11(12):2629-34. PubMed ID: 9021364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception.
    Subakir SB; Hadisaputra W; Siregar B; Irawati D; Santoso DI; Cornain S; Affandi B
    Hum Reprod; 1995 Oct; 10(10):2579-83. PubMed ID: 8567774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation?
    Heikinheimo O; Ranta S; Moo-Young A; Lähteenmäki P; Gordon K
    Hum Reprod; 1999 Aug; 14(8):1993-7. PubMed ID: 10438416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
    Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
    Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women.
    Brache V; Merkatz R; Kumar N; Jesam C; Sussman H; Hoskin E; Roberts K; Alami M; Taylor D; Jorge A; Croxatto H; Lorange E; Mishell DR; Sitruk-Ware R
    Contraception; 2015 Oct; 92(4):289-97. PubMed ID: 26032952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.